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case-control study in a national screening
program
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Abstract
Background: Breast cancer comprises several molecular subtypes with different prognoses and possibly different
etiology. Reproductive and hormonal factors are associated with breast cancer overall, and with luminal subtypes,
but the associations with other subtypes are unclear. We used data from a national screening program to conduct
a large nested case-control study.
Methods: We conducted a nested case-control study on participants in the Norwegian Breast Cancer Screening
Program in 2006 − 2014. There was information on estrogen receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) for 4748 cases of breast cancer. Breast cancer subtypes were defined as
luminal A-like (ER+ PR+ HER2-), luminal B-like (ER+ PR- HER2- or ER+ PR+/PR-HER2+), HER2-positive (ER- PR- HER2+)
and triple-negative (ER- PR- HER2-). Conditional logistic regression was used to estimate odds ratios (ORs) of breast
cancer associated with age at first birth, number of pregnancies, oral contraceptive use, intrauterine devices and
menopausal hormone therapy. Analyses were adjusted for age, body mass index, education, age at menarche,
number of pregnancies and menopausal status.
Results: Number of pregnancies was inversely associated with relative risk of luminal-like breast cancers (p-trend
≤0.02), and although not statistically significant, with HER2-positive (OR = 0.60, 95% CI 0.31–1.19) and triple-negative
cancer (OR = 0.70, 95% CI 0.41–1.21). Women who had ≥4 pregnancies were at >40% lower risk of luminal-like and
HER2-positive cancers than women who had never been pregnant. However, there was a larger discrepancy
between tumor subtypes with menopausal hormone use. Women who used estrogen and progesterone therapy
(EPT) had almost threefold increased risk of luminal A-like cancer (OR = 2.92, 95% CI 2.36–3.62) compared to never-
users, but were not at elevated risk of HER2-positive (OR = 0.88, 95% CI 0.33–2.30) or triple-negative (OR = 0.92, 95%
CI 0.43 − 1.98) subtypes.
Conclusions: Reproductive factors were to some extent associated with all subtypes; the strongest trends were
with luminal-like subtypes. Hormone therapy use was strongly associated with risk of luminal-like breast cancer, and
less so with risk of HER2-positive or triple-negative cancer. There are clearly some, but possibly limited, etiologic
differences between subtypes, with the greatest contrast between luminal A-like and triple-negative subtypes.
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Background
There is substantial evidence for a role of female hor-
mones in the etiology of breast cancer. Reproductive
factors, such as early age at menarche, nulliparity,
and late age at first birth [1–3] are all believed to be
associated with breast cancer risk through hormonal
mechanisms. Current use of oral contraceptives is as-
sociated with some increased risk of breast cancer
[4–6]. Likewise, combined postmenopausal hormone
therapy (estrogen and progesterone), increases the
risk of breast cancer [7–16]. However, breast cancer
consists of several molecular subtypes that have very
different prognoses [17–23]. It is less clear whether
these various subtypes have different etiologies. There
have been two main challenges in previous literature:
the various definitions used to define breast cancer
subtypes, and the lack of power to examine the effect
on all subtypes.
In earlier studies, subtypes were defined by immu-
nohistochemical analysis (IHC) of the two hormone
receptors only, i.e. the estrogen receptor (ER) and
the progesterone receptor (PR) [24–31]. It is only in
recent years that studies have been conducted in-
corporating data on human epidermal growth factor
receptor 2 (HER2) status [32–38], with a few having
included other additional molecular markers [3, 34,
39–44]. However, most studies so far have not been
able to run molecular expression studies on a large
scale. This may not be necessary however, because
there is a large degree of overlap between the immu-
nohistochemical subtypes defined by ER, PR, and
HER2 status and those identified by molecular ex-
pression studies [18–21, 45]. However, a challenge
has been that investigators have used various defini-
tions and specific markers to define breast cancer
subtypes, such as luminal B tumors. Further, using
the molecular terms luminal A, B, or basal gives the
impression that they are defined using molecular
expression markers, whereas they are based on IHC.
Investigators at the St. Gallen meeting in 2013 there-
fore suggested that the term “like” should be added
to the molecularly derived “luminal” subtype names
(e.g. “luminal A-like”, “luminal B-like”) to indicate
that IHC was used to define these subtypes [46] and
hence, that they are proxies of the molecular
subtypes.
Another challenge has been that many studies have not
had adequate power to assess the effect of risk factors on
all subtypes, which makes it difficult to determine the
effect of risk factors on the less common subtypes. The
overall published evidence [7, 8, 10, 47–50] seems to
be consistent with luminal A-like cancers having a
hormonal etiology, but the association between
hormonal factors and other subtypes, in particular
luminal B-like disease, HER2-positive disease, and
triple-negative cancer, is less clear. Specifically, repro-
ductive factors such as parity and early age at first
birth have been associated with reduced risk of
luminal A-like disease. There is less evidence of a
protective effect of parity on luminal B-like and
HER2-positive cancers and parity has consistently
been found not to protect against triple-negative
disease [7, 47–50]. There is some, albeit inconsistent,
evidence that older age at menarche and breastfeeding
may protect against all subtypes [7, 8, 47, 49–52]
suggesting that these protective effects may work
through non-hormonal mechanisms. The use of
menopausal hormone therapy has been consistently
associated with an increased risk of luminal A-like
breast cancer, but the evidence is less clear for risk of
luminal B-like, HER2-positive and triple-negative
breast cancer [10, 47, 49].
We decided to take advantage of a national screen-
ing program in Norway to examine potential associa-
tions between reproductive and hormonal factors
and the various breast cancer subtypes - specifically,
luminal A-like, luminal B-like HER2-negative,
luminal B-like HER2-positive, HER2-positive, and
triple-negative disease - in a large study. We there-
fore conducted a large nested case-control study
within the Norwegian Breast Cancer Screening
Program.
Methods
Study population
The Cancer Registry of Norway (CRN) is responsible
for the administration of the Norwegian Breast Can-
cer Screening Program [53]. Women aged 50–69
years are invited to undergo two-view mammography
screening every 2 years. From August 2006, women,
who underwent mammographic screening in the na-
tional program were asked to complete a question-
naire on a number of standard breast cancer risk
factors, and another questionnaire on current expos-
ure variables at subsequent screenings. For the
current study cohort, women who had participated
in the Norwegian Breast Cancer Screening Program
during 2006 to 2014 and had completed these ques-
tionnaires were eligible for inclusion. The study co-
hort comprised a total of 344,348 eligible women.
Information on cancer cases was obtained through
linkage to the population-based CRN records using
the unique 11-digit personal identification number
assigned to all residents at time of birth. This link-
age also included information on vital status, includ-
ing date and cause of death/date of emigration if
applicable. Reporting of cancer to the CRN is
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mandatory by law, and the registry is considered to
be 98.8% complete [54].
All women aged 50–69 years who are included in the
National Population Registry are invited to undergo
screening as part of the Norwegian Breast Cancer
Screening Program every 2 years. The average attend-
ance rate in each round is about 76%.
We conducted a nested case-control study within
the study cohort. Only women with no history of
ductal carcinoma in situ prior to the study start (1
January 2006) and no history of diagnosis of another
invasive cancer (except non-melanoma skin cancer)
were eligible for the study. The cases were women
diagnosed with a first occurrence of invasive breast
cancer (ICD10: C50) during the study period, with
information on ER, PR, and HER2 status (see subse-
quent text). For each woman with breast cancer, we
randomly selected five controls individually matched
to cases by year of birth (+/- 3 years) and year of
last screening before breast cancer diagnosis (+/-
3 years). Controls had to be alive and resident in the
country at the time of the diagnosis of breast cancer
in the matching case. We ended up with 6471 pa-
tients with breast cancer (cases) and 32,355 controls.
The study was approved by the Regional Committee
for Medical and Health Research Ethics in the
South-East Health Region of Norway.
Tumor receptor status ascertainment
Information on ER, PR and HER2 status was assessed
by IHC and extracted from pathology reports submit-
ted to the CRN. From 2006 to January 2012, tumors
were classified as ER-negative if there was <10% re-
activity. From February 2012 onwards, the threshold
for ER-negative tumors was changed to <1% reactiv-
ity as a result of change in the treatment protocols
for patients attending clinics in Norway. We used
these official thresholds. PR-negative tumors were de-
fined as those with reactivity of <10%, and PR-
positive tumors as those with reactivity ≥10%. HER2
expression status was determined at each laboratory
with IHC and/or in situ hybridization. Cases with no
(0) or weak (1+) immunostaining were defined as
HER2-negative, while cases with moderate (2+) or
strong immunostaining (3+) were defined as HER2-
positive. In situ hybridization (fluorescence (FISH),
chromogenic (CISH), or silver (SISH) in situ
hybridization methods) was usually used to confirm
HER2 status if IHC yielded 2+ results. If IHC was 2+
and FISH, CISH, or SISH were missing, or if IHC
was missing but FISH, CISH, or SISH were positive,
the tumor was classified as HER2-positive. If IHC
was 2+ and FISH, CISH, and SISH were negative, the
tumor was regarded as HER2-negative. Data on Ki-67
were recorded by the CRN from late 2011 and
therefore, we did not include this marker in our
analysis.
Risk factors
Our primary exposures of interest were hormonal
risk factors including reproductive factors (age at
first birth, number of pregnancies, breastfeeding,
menopausal status), and other hormonal factors (use
of oral contraceptives, intrauterine devices (IUD) and
menopausal hormone therapy use). Menopausal
hormone therapy use included use of estrogen alone
(estrogen therapy, ET), or use of combined estrogen
and progestin therapy (EPT). For current exposures
we chose the questionnaire at the last screening
before breast cancer diagnosis for the cases and the
corresponding time for the controls. If the question-
naire or any values were missing, information was
used from the previous screening questionnaire.
Menopausal status was defined according to whether
or not women were still menstruating, or whether
they menstruated irregularly. Menopausal age was
defined as the age when menstruation ended.
Confounders and missing values
We considered age at screening (50–54, 55–59, 60–
64, or 65–70 years), body mass index (BMI) at
screening (≤22, 23–25, 26-28, or >28), education (no
education/primary school, high school, or bachelor’s/
master’s degree), age at menarche (9–12, 13, 14, or
15–18 years), number of pregnancies lasting at least
six months (never pregnant, 1, 2, 3, or ≥4) and meno-
pausal status (premenopausal, perimenopausal, or
postmenopausal) as potential confounders and ad-
justed for these when appropriate. We tried to con-
trol more tightly for age at screening using a
continuous variable, but the results remained largely
the same, and we therefore retained the 5-year
categories.
Women with missing values for an exposure vari-
able were excluded from the analyses of that vari-
able, while women with missing information on the
potential confounding variables listed previously
were excluded from all analyses. Of the 6471 pa-
tients with breast cancer, we excluded women due to
missing information on the following variables: BMI
(n = 532 patients), age at menarche (n = 298 patients),
education (n = 66 patients), number of pregnancies
(n = 164 patients), and menopausal status (n = 59 pa-
tients). This left us with 5352 women with breast
cancer (cases) for analysis. Of the 32,355 controls,
we excluded controls based on missing information
on the following: BMI (n = 3296 controls), age at
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menarche (n = 1641 controls), education (n = 371
controls), number of pregnancies (n = 779 controls),
and menopausal status (n = 336 controls). This left
us with 25,932 controls for analysis.
The cases were categorized by breast cancer sub-
type using a modified version of the classification of
clinically defined subtypes proposed at the St. Gallen
meeting in 2013 [46]. Of the 5352 cases of breast
cancer, 604 had unknown hormone receptor (i.e. ER
and/or PR) and HER2 status or could not be classi-
fied into the breast cancer subtypes. There were
4748 women with breast cancer classified into the
following subtypes: 2985 women with luminal A-like
breast cancer (ER+ PR+ HER2-), 758 women with
luminal B-like HER2-negative breast cancer (ER+
PR- HER2-), 396 women with luminal B-like HER2-
positive breast cancer (ER+ PR+/PR- HER2+), 223
women with HER2-positive breast cancer (ER- PR-
HER2+) and 386 women with triple-negative breast
cancer (ER- PR- HER2-). As we did not have Ki-67
results, we conducted sensitivity analysis where we
added grade to the luminal subtype definitions in an
attempt to better separate out these subtypes, using
the definitions from the St. Gallen 2013 meeting
[46]. In this analysis luminal A-like subtype was de-
fined as ER+ PR+ HER2-, low or medium grade, lu-
minal B-like HER2-negative as ER+ PR- HER2-, high
grade, and luminal B-like HER2-positive as ER+ PR-/
PR+ HER2+, any grade.
Statistical analyses
We used conditional logistic regression to estimate
odds ratios (with 95% confidence intervals (CI)) as a
measure of relative risk associated with various expo-
sures. Trend tests were performed by fitting ordinal
values corresponding to exposure categories and test-
ing whether the slope coefficient differed from zero.
To test for heterogeneity between breast cancer
subtypes we ran case–case analyses, comparing each
subtype to the luminal-A-like subtype. We used likeli-
hood ratio tests comparing the likelihood ratio of the
case–case model with confounders only to that of the
adjusted case–case model with the exposure variable.
We considered a two-sided p value <0.05 as statisti-
cally significant.
Because we used conditional logistic regression we in-
cluded all women in the risk estimates (e.g. women who
were never pregnant were included in analysis of age at
first birth, women who never used oral contraceptives
(OC) were included in analysis of age at the start of OC,
and premenopausal women were included in analysis of
age at menopause), but they were not included in the
trend test (dummy variables were added into the
analysis).
Results
BMI, age at first birth, education, age at menopause,
duration of use of oral contraceptives and intrauterine
devices, and menopausal hormone therapy use were
positively associated with overall breast cancer risk (i.e.
all subtypes combined) whereas age at menarche,
number of pregnancies and postmenopausal status were
associated with a decreased risk (Table 1).
Number of pregnancies was inversely associated
with risk of breast cancer overall and risk of several
breast cancer subtypes (Table 2). Compared to
women who had never been pregnant, those with ≥4
pregnancies had about 40% or lower risk of develop-
ing luminal-like breast cancer, and all three tests for
trend were statistically significant (Table 2). There
were similar, but non-significant protective associa-
tions also with HER2-positive and triple-negative
tumors, but neither the point estimate for the top
category (≥4 pregnancies: OR = 0.60, 95% CI 0.31–
1.19 and OR = 0.70, 95% CI 0.41–1.21, respectively),
nor the trend for number of pregnancies was statisti-
cally significant. The test for heterogeneity comparing
triple-negative cancer to luminal A-like cancer was
statistically significant.
Later age at first birth was associated with an in-
creased risk of breast cancer overall and with several
breast cancer subtypes (Table 2). Compared to those
with an early first birth (≤20 years), women with a
later age at first birth (>30 years) were at slightly in-
creased risk of luminal A-like (OR = 1.19, 95% CI
0.99–1.43) and luminal B-like HER2-negative breast
cancer (OR = 1.60, 95% CI 1.10–2.32, p-trend = 0.07
and 0.01, respectively). The ORs associated with the
oldest age at first birth (>30 years) were also similarly
elevated, but not significantly so, for HER2-positive
(OR = 1.67, 95% CI 0.89–3.12) and triple-negative
(OR = 1.47, 95% CI 0.88–2.47) subtypes (p-trend =
0.49 and 0.16, respectively). However, the test for
heterogeneity comparing each subtype to luminal A-
like breast cancer was not statistically significant for
age at first birth.
Duration of breastfeeding was not statistically
significantly associated with breast cancer overall (p-
trend = 0.14) (Table 1) or with any of the subtypes
(Table 2). Postmenopausal status was associated with
a statistically significantly reduced risk of breast can-
cer overall (Table 1) and of luminal A-like breast
cancer compared to being premenopausal (OR = 0.51,
95% CI 0.43–0.60), while no association was observed
for any of the other subtypes, and all tests for hetero-
geneity were statistically significant. Age at meno-
pause, comparing women >52 to women <47 years
old was positively associated with risk of luminal B-
like HER2-positive (OR = 1.70, 95% CI 1.13–2.55, p-
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Table 1 Adjusted odds ratios (ORs) and 95% confidence intervals (CI) for association between breast cancer overall and education
and reproductive and hormonal risk factors
Characteristics Overall
Total (n) Controls (n) Cases (n) OR* 95% CI
Education
No education/primary school 8584 7192 1392 1 Ref
High school 12,781 10,582 2199 1.07 (0.99, 1.15)
University Bachelor’s degree 6179 5081 1098 1.11 (1.01, 1.22)
University Master’s degree 3740 3077 663 1.10 (0.98, 1.22)
p-trend* 0.03
BMI (kg/m2)
< = 22 5141 4333 808 1 Reference
23–25 9655 8075 1580 1.07 (0.98, 1.18)
26–28 8131 6694 1437 1.19 (1.08, 1.32)
>28 8357 6830 1527 1.23 (1.12, 1.36)
p-trend <0.0001
Age at menarche (years)
9–12 9296 7615 1681 1 Reference
13 8628 7157 1471 0.93 (0.86, 1.01)
14 7704 6439 1265 0.89 (0.82, 0.97)
15–18 5656 4721 935 0.90 (0.82, 0.98)
p-trend 0.01
Age at first birth (years)
13–20 8413 7085 1328 1 Reference
21–22 4994 4170 824 1.04 (0.94, 1.15)
23–25 6673 5580 1093 1.02 (0.93, 1.12)
26–30 5440 4497 943 1.09 (0.98, 1.20)
31–50 2070 1641 429 1.29 (1.12, 1.48)
Never given birth (nulliparous) 2730 2144 586 1.73 (1.49, 2.01)
p-trenda 0.003
Number of pregnancies lasting 6+ months
0 2730 2144 586 1 Reference
1 3584 2911 673 0.83 (0.73, 0.94)
2 13499 11000 2301 0.76 (0.68, 0.84)
3 8307 6956 1351 0.71 (0.63, 0.79)
>4 3164 2723 441 0.59 (0.51, 0.68)
p-trend <0.0001
Parous women only
Duration of breastfeeding (months)
Parous no breastfeeding 2201 1840 361 1 Reference
1–6 6872 5775 1097 0.97 (0.84, 1.11)
7–12 6662 5452 1210 1.16 (1.01, 1.34)
13–20 5466 4544 922 1.08 (0.93, 1.25)
21–30 3620 3043 577 1.04 (0.88, 1.22)
>30 2067 1736 331 1.10 (0.91, 1.33)
p-trend 0.14
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Table 1 Adjusted odds ratios (ORs) and 95% confidence intervals (CI) for association between breast cancer overall and education
and reproductive and hormonal risk factors (Continued)
Menopausal status
Premenopausal 2568 2035 533 1 Reference
Perimenopausal 2279 1876 403 0.73 (0.63, 0.86)
Postmenopausal 26437 22000 4416 0.66 (0.59, 0.75)
p-trend <0.0001
Age at menopause (years)
<47 5412 4595 817 1 Reference
47–49 5151 4324 827 1.10 (0.99, 1.22)
50–52 9831 8218 1613 1.13 (1.03, 1.24)
>52 6663 5508 1155 1.15 (1.04, 1.28)
Premenopausal 2568 2035 533 1.81 (1.57, 2.10)
p-trendb 0.01
Age at start of oral contraceptives (years)
14–18 3097 2577 520 1 Reference
19–20 3356 2686 670 1.19 (1.02, 1.38)
21–24 4190 3490 700 0.95 (0.82, 1.11)
25–50 4307 3590 717 0.91 (0.77, 1.07)
Never used 14532 12000 2443 0.95 (0.85, 1.07)
p-trenda 0.06
Duration of oral contraceptives (years)
Never used 14532 12000 2443 1 Reference
<2 4019 3405 614 0.89 (0.81, 0.99)
2–5 3758 3120 638 1.02 (0.92, 1.13)
6–10 3453 2834 619 1.10 (0.99, 1.22)
>10 2718 2203 515 1.11 (1.00, 1.25)
p-trend 0.01
Age at start of intrauterine device (years)
14–28 1340 1120 220 1 Reference
29–35 1422 1174 248 1.03 (0.84, 1.27)
36–42 1193 965 228 1.18 (0.95, 1.46)
43–50 1052 859 193 1.06 (0.85, 1.33)
Never used 21734 18000 3693 0.99 (0.84, 1.16)
p-trenda 0.27
Duration of intrauterine device (years)
Never used 21734 18000 3693 1 Reference
<2 729 612 117 0.92 (0.75, 1.14)
2–5 969 791 178 1.07 (0.90, 1.28)
6–10 1403 1158 245 1.10 (0.95, 1.28)
>10 1753 1432 321 1.14 (0.99, 1.30)
p-trend 0.03
Hormone therapy use
Never 15688 13000 2487 1 Reference
Past 10548 8656 1892 1.16 (1.08, 1.25)
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trend = 0.01) and HER2-positive (OR = 2.36, 95% CI
1.33–4.21, p-trend = 0.004) subtypes (Table 2).
Duration of oral contraceptive use and use of an
IUD, were associated with a slight increased risk of
breast cancer overall (Table 1), with 10% elevated
ORs among women with the longest duration of use.
The effect estimates for long duration of oral contra-
ceptive use were similar, but not statistically signifi-
cant, for luminal A-like (OR = 1.11, 95% CI 0.96–
1.29) and luminal B-like HER2-negative (OR = 1.12,
95% CI 0.81–1.54) subtypes. Women who had used
an IUD for more than 10 years had an increased risk
of luminal A-like breast cancer compared to never
users (OR = 1.35, 95% CI 1.14–1.61) (Table 3). We
observed no evidence of any clear associations for
the other subtypes, and in fact a reduced OR for the
luminal B-like HER2-positive (OR = 0.51, 95% CI
0.27–0.96) subtype (p-heterogeneity with luminal A-
like breast cancer = 0.009) (Table 3).
Compared to women who had never used EPT,
current use of EPT was associated with an increased
risk (OR = 2.32, 95% CI 1.97–2.72) of breast cancer
overall (Table 1) and an increased risk of luminal A-
like breast cancer (OR = 2.92, 95% CI 2.36–3.62)
(Table 3). The ORs for both luminal B-like subtypes
were about 1.7, but this was only statistically signifi-
cant for the luminal B-like HER2-negative subtype.
There was no increased risk of triple-negative breast
cancer with the use of EPT (p-heterogeneity = 0.006).
Previous studies have suggested that the effect of
menopausal hormone therapy may be modified by
BMI, with stronger risk estimates in lean than in
obese women. We therefore examined the effect of
duration of EPT in different BMI strata. For breast
cancer overall, the ORs associated with longer dur-
ation of EPT was significantly higher in lean (BMI
<25) than in obese (BMI ≥25) women (p for inter-
action = 0.001) (Table 4). We observed similar effect
modifications by BMI in luminal A-like and luminal
B-like HER2-negative breast cancer. There was no
evidence that BMI modified the associations between
duration of EPT and risk of any of the other sub-
types (Table 4).
When we added grade to the luminal A-like and both
luminal B-like definitions, the results changed slightly,
but were largely the same (Appendix). The largest differ-
ence was a slightly stronger effect of current EPT on the
luminal A-like subtype (OR = 3.03 when grade was
included in the definition versus OR = 2.90 when it
was not).
Among the patients (cases), 38% (n = 1813) were
diagnosed within a month of completing the ques-
tionnaire. Because these women could have been
symptomatic when they completed their question-
naire, we ran a sensitivity analysis excluding these
women. However, this did not affect the results
(results not shown).
Discussion
In this population-based study within a national
screening program, we had information on 4748 pa-
tients with breast cancer, which makes it one of the
Table 1 Adjusted odds ratios (ORs) and 95% confidence intervals (CI) for association between breast cancer overall and education
and reproductive and hormonal risk factors (Continued)
Estrogen current 1468 1219 249 1.03 (0.88, 1.20)
Estrogen and progesterone current 953 661 292 2.32 (1.97, 2.72)
p-trend <0.0001
Duration of hormone therapy (years)
Never used 15688 13000 2487 1 Reference
< =3 3636 3066 570 1.00 (0.90, 1.10)
4–8 2449 2013 436 1.17 (1.03, 1.30)
>8 4060 3151 909 1.58 (1.42, 1.70)
p-trend <0.0001
Duration of estrogen and progesterone therapy (years)
Never used 15688 13000 2487 1 Reference
< =5 4288 3552 736 1.13 (1.02, 1.25)
>5 4189 3238 951 1.61 (1.46, 1.78)
p-trend <0.0001
aThe category Never used was not included in the analysis of p-trend. bThe category Premenopausal was not included in the analysis of p-trend. *p for trend and
OR mutually adjusted for age (50–54, 55–59, 60–64, 65–70 years at screening), body mass index (BMI) (≤22, 23–25, 26–28, >28 at screening), education (no
education/primary school, high school, bachelor’s or master’s degree), age at menarche (9–12, 13, 14, 15–18 years), number of pregnancies (0, 1, 2, 3, ≥4),
menopausal status (premenopausal, perimenopausal, postmenopausal)
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Table 2 Adjusted odds ratios (OR) and 95% confidence intervals (CI) for association between breast cancer subtypes associated and reproductive factors
Luminal A-like Luminal B-like HER2-negative Luminal B-like HER2-positive HER2-positive Triple-negative
ER+ PR+ HER2- ER+ PR- HER2- ER+ PR+/PR- HER2+ ER- PR- HER2+ ER- PR- HER2-
Controls
(n)
Cases
(n)
OR* 95% CI Controls
(n)
Cases
(n)
OR 95% CI Controls
(n)
Cases
(n)
OR 95% CI Controls (n) Cases
(n)
OR 95% CI Controls
(n)
Cases
(n)
OR 95% CI
Age at first birth (years)
13–20 3951 746 1 Reference 1001 169 1 Reference 553 96 1 Reference 279 54 1 Reference 495 95 1 Reference
21–22 2277 460 1.04 (0.91, 1.18) 620 120 1.22 (0.93, 1.59) 305 51 0.97 (0.65, 1.43) 170 32 0.97 (0.58, 1.62) 326 65 1.10 (0.77, 1.57)
23–25 3152 591 0.97 (0.85, 1.10) 759 157 1.29 (1.00, 1.67) 437 92 1.27 (0.90, 1.78) 222 36 0.75 (0.46, 1.22) 393 86 1.27 (0.89, 1.81)
26–30 2473 547 1.12 (0.98, 1.28) 647 141 1.30 (0.99, 1.71) 343 62 1.21 (0.82, 1.78) 216 41 0.97 (0.59, 1.58) 318 63 1.16 (0.79, 1.70)
31–50 937 238 1.19 (0.99, 1.43) 223 60 1.60 (1.10, 2.32) 127 32 1.64 (0.98, 2.74) 63 23 1.67 (0.89, 3.12) 120 29 1.47 (0.88, 2.47)
Never (nulliparous) 1199 328 1.76 (1.44, 2.15) 303 89 1.96 (1.31, 2.91) 164 49 2.74 (1.57, 4.78) 84 27 1.82 (0.85, 3.88) 144 34 1.58 (0.89, 2.81)
p-trenda 0.07 0.01 0.06 0.49 0.16
p-heterogeneity# 0.19 0.19 0.31 0.68
Number of pregnancies lasting 6+ months
0 1199 328 1 Reference 303 89 1 Reference 164 49 1 Reference 84 27 1 Reference 144 34 1 Reference
1 1596 397 0.91 (0.77, 1.08) 426 84 0.68 (0.48, 0.96) 229 42 0.53 (0.33, 0.86) 128 20 0.50 (0.26, 0.96) 224 41 0.70 (0.42, 1.16)
2 6266 1302 0.76 (0.66, 0.88) 1602 323 0.68 (0.52, 0.90) 842 185 0.71 (0.49, 1.04) 426 97 0.78 (0.47, 1.29) 813 158 0.77 (0.50, 1.18)
3 3883 721 0.66 (0.57, 0.77) 950 197 0.69 (0.52, 0.93) 528 89 0.54 (0.36, 0.82) 319 60 0.61 (0.36, 1.03) 477 117 0.98 (0.63, 1.53)
>4 1518 237 0.56 (0.46, 0.68) 383 65 0.58 (0.40, 0.84) 225 31 0.42 (0.25, 0.70) 98 19 0.60 (0.31, 1.19) 196 36 0.70 (0.41, 1.21)
p-trend <0.0001 0.02 0.002 0.19 0.88
p-heterogeneity 0.31 0.42 0.34 0.03
Parous women only
Duration breastfeeding (months)
No breastfeeding 997 204 1 Reference 260 51 1 Reference 146 33 1 Reference 78 10 1 Reference 135 24 1 Reference
1–6 3145 607 0.95 (0.79, 1.15) 831 170 1.01 (0.70, 1.45) 449 74 0.66 (0.40, 1.07) 243 37 1.42 (0.63, 3.18) 467 80 1.01 (0.60, 1.71)
7 − 12 3108 663 1.09 (0.91, 1.31) 763 158 1.05 (0.73, 1.51) 427 98 0.83 (0.51, 1.33) 215 52 2.25 (1.02, 4.99) 359 95 1.65 (0.98, 2.78)
13 − 20 2583 496 1.02 (0.83, 1.24) 654 130 0.98 (0.67, 1.44) 343 77 0.90 (0.54, 1.49) 156 48 2.51 (1.11, 5.68) 308 69 1.29 (0.74, 2.23)
21 − 30 1700 319 1.03 (0.83, 1.28) 399 79 0.97 (0.64, 1.46) 240 37 0.60 (0.33, 1.10) 147 28 1.78 (0.74, 4.28) 222 44 1.18 (0.65, 2.15)
>30 966 195 1.15 (0.89, 1.48) 250 48 1.03 (0.63, 1.69) 121 16 0.69 (0.33, 1.47) 70 13 1.82 (0.67, 4.97) 123 24 1.19 (0.58, 2.44)
p-trend 0.22 0.90 0.63 0.12 0.52
p-heterogeneity 0.85 0.25 0.56 0.84
Menopausal status
Premenopausal 1171 351 1 Reference 208 47 1 Reference 173 32 1 Reference 100 18 1 Reference 130 29 1 Reference
Perimenopausal 1055 229 0.61 (0.50, 0.74) 225 50 0.95 (0.60, 1.51) 152 26 0.86 (0.47, 1.54) 79 20 1.41 (0.67, 2.94) 143 37 1.13 (0.64, 1.99)
Postmenopausal 12000 2405 0.51 (0.43, 0.60) 3231 661 0.84 (0.58, 1.23) 1663 338 1.11 (0.69, 1.78) 876 185 1.21 (0.66, 2.23) 1581 320 0.82 (0.50, 1.33)
p-trend <0.0001 0.30 0.46 0.71 0.21
p-heterogeneity <0.0001 0.01 0.001 0.003
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Table 2 Adjusted odds ratios (OR) and 95% confidence intervals (CI) for association between breast cancer subtypes associated and reproductive factors (Continued)
Age at menopause (years)
<47 2558 450 1 Reference 638 136 1 Reference 333 47 1 Reference 203 22 1 Reference 336 61 1 Reference
47–49 2393 449 1.09 (0.94, 1.26) 637 128 0.98 (0.74, 1.29) 321 60 1.48 (0.96, 2.27) 180 39 2.05 (1.14, 3.70) 291 72 1.50 (1.01, 2.24)
50–52 4571 870 1.11 (0.98, 1.26) 1162 241 0.98 (0.77, 1.24) 644 131 1.59 (1.09, 2.32) 324 76 2.21 (1.31, 3.75) 611 102 1.04 (0.72, 1.49)
>52 3051 633 1.12 (0.97, 1.28) 840 164 0.95 (0.73, 1.24) 415 94 1.70 (1.13, 2.55) 202 48 2.36 (1.33, 4.21) 395 88 1.38 (0.94, 2.01)
Never (premenopausal) 1171 351 2.34 (1.93, 2.85) 208 47 1.17 (0.76, 1.80) 173 32 1.50 (0.86, 2.61) 100 18 1.76 (0.81, 3.80) 130 29 1.55 (0.88, 2.72)
p-trenda 0.12 0.72 0.01 0.004 0.38
p-heterogeneity 0.70 0.09 0.08 0.28
aThe category Never was not included in the analysis of p-trend. *p for trend and OR mutually adjusted for age (50–54, 55–59, 60–64, 65–70 years at screening), body mass index (BMI) (≤22, 23–25, 26–28, >28 at
screening), education (no education/primary school, high school, bachelor or master’s degree), age at menarche (9–12, 13, 14, 15–18 years), number of pregnancies (0, 1, 2, 3, ≥4), menopausal status (premenopausal,
perimenopausal, postmenopausal). #p for heterogeneity across subtypes was determined in a case − case model (see “Methods”). ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor
receptor 2
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Table 3 Adjusted odds ratios (OR) and 95% confidence intervals (CI) for association between breast cancer subtypes and oral contraceptives and hormone therapy
Luminal A-like Luminal B-like HER2-negative Luminal B-like HER2-positive HER2-positive Triple-negative
ER+ PR+ HER2- ER+ PR- HER2- ER+ PR+/PR- HER2+ ER- PR- HER2+ ER- PR- HER2-
Controls
(n)
Cases
(n)
OR* 95% CI Controls
(n)
Cases
(n)
OR 95% CI Controls
(n)
Cases
(n)
OR 95% CI Controls
(n)
Cases
(n)
OR 95% CI Controls
(n)
Cases
(n)
OR 95% CI
Age at start of oral contraceptives (years)
14–18 1476 285 1 Reference 334 65 1 Reference 187 45 1 Reference 128 17 1 Reference 180 55 1 Reference
19–20 1462 387 1.33 (1.11, 1.59) 367 87 1.20 (0.82, 1.75) 230 49 0.90 (0.55, 1.45) 133 27 1.52 (0.75, 3.10) 206 46 0.67 (0.42, 1.07)
21–24 1959 405 1.05 (0.87, 1.25) 458 92 1.04 (0.71, 1.53) 295 45 0.62 (0.37, 1.02) 130 24 1.45 (0.69, 3.04) 253 41 0.44 (0.27, 0.74)
25–50 1993 397 0.99 (0.83, 1.20) 536 102 0.97 (0.66, 1.43) 296 58 0.80 (0.49, 1.32) 114 27 2.23 (1.06, 4.71) 258 58 0.63 (0.39, 1.03)
Never used 6715 1344 1.01 (0.86, 1.19) 1758 363 0.99 (0.71, 1.38) 876 180 0.82 (0.53, 1.27) 501 115 2.05 (1.08, 3.89) 860 165 0.54 (0.36, 0.81)
p-trenda 0.09 0.43 0.71 0.02 0.03
p-heterogeneity# 0.60 0.52 0.07 0.02
Duration of oral contraceptives (years)
Never used 6715 1344 1 Reference 1758 363 1 Reference 876 180 1 Reference 501 115 1 Reference 860 165 1 Reference
<2 1839 364 0.97 (0.85, 1.11) 482 80 0.82 (0.62, 1.08) 275 34 0.64 (0.42, 0.97) 151 18 0.47 (0.27, 0.81) 263 43 0.85 (0.58, 1.26)
2–5 1753 361 1.03 (0.90, 1.18) 435 88 1.01 (0.77, 1.33) 233 48 0.94 (0.64, 1.37) 113 17 0.61 (0.34, 1.09) 228 56 1.32 (0.92, 1.89)
6–10 1568 332 1.06 (0.92, 1.23) 388 80 1.03 (0.77, 1.37) 240 56 1.23 (0.85, 1.76) 121 35 1.07 (0.66, 1.73) 203 47 1.20 (0.82, 1.76)
>10 1266 298 1.11 (0.96, 1.29) 271 62 1.12 (0.81, 1.54) 204 45 0.95 (0.64, 1.42) 82 19 1.02 (0.56, 1.86) 149 38 1.25 (0.82, 1.90)
p-trend* 0.13 0.51 0.57 0.91 0.11
p-heterogeneity# 0.61 0.10 0.003 0.56
Age at start of intrauterine device (years)
14–28 612 125 1 Reference 152 28 1 Reference 82 14 1 Reference 55 12 1 Reference 88 19 1 Reference
29–35 681 143 0.97 (0.73, 1.28) 152 39 1.31 (0.75, 2.30) 93 10 0.76 (0.30, 1.90) 46 7 0.74 (0.24, 2.25) 78 25 1.42 (0.70, 2.88)
36–42 532 147 1.33 (1.00, 1.77) 114 21 0.83 (0.43, 1.58) 89 19 1.34 (0.60, 3.01) 43 7 0.75 (0.26, 2.16) 78 12 0.70 (0.31, 1.58)
43 − 50 456 121 1.16 (0.86, 1.56) 136 25 0.86 (0.46, 1.59) 70 11 1.06 (0.42, 2.70) 39 7 0.94 (0.32, 2.78) 70 14 0.94 (0.42, 2.12)
Never used 10000 2025 0.93 (0.75, 1.15) 2600 529 0.94 (0.61, 1.45) 1368 284 1.36 (0.72, 2.56) 729 153 1.10 (0.56, 2.16) 1279 267 0.94 (0.55, 1.61)
p-trenda 0.07 0.34 0.10 0.40 0.45
p-heterogeneity# 0.22 0.12 0.20 0.38
Duration of intrauterine device (years)
Never used 10000 2025 1 Reference 2600 529 1 Reference 1368 284 1 Reference 729 153 1 Reference 1279 267 1 Reference
<2 341 64 0.91 (0.69, 1.21) 83 16 0.86 (0.49, 1.52) 56 13 1.23 (0.62, 2.43) 33 5 0.84 (0.31, 2.32) 37 7 0.90 (0.38, 2.13)
2–5 432 104 1.17 (0.93, 1.48) 112 21 0.95 (0.58, 1.56) 62 11 0.96 (0.47, 1.94) 36 7 0.81 (0.34, 1.91) 57 21 1.79 (1.01, 3.16)
6–10 615 140 1.16 (0.95, 1.42) 153 40 1.37 (0.94, 2.01) 89 15 0.86 (0.46, 1.59) 53 8 0.62 (0.27, 1.43) 99 20 1.23 (0.72, 2.11)
>10 820 212 1.35 (1.14, 1.61) 176 31 0.96 (0.63, 1.46) 111 12 0.51 (0.27, 0.96) 63 12 0.73 (0.37, 1.47) 120 20 0.75 (0.44, 1.28)
p-trend <0.0001 0.52 0.06 0.18 0.98
p-heterogeneity# 0.08 0.01 0.65 0.22
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Table 3 Adjusted odds ratios (OR) and 95% confidence intervals (CI) for association between breast cancer subtypes and oral contraceptives and hormone therapy (Continued)
Hormone therapy use
Never 7411 1356 1 Reference 1762 356 1 Reference 1010 195 1 Reference 573 113 1 Reference 991 196 1 Reference
Past 4809 1086 1.27 (1.15, 1.40) 1361 276 0.98 (0.81, 1.18) 688 142 1.07 (0.81, 1.42) 319 65 0.88 (0.60, 1.30) 575 126 1.04 (0.79, 1.38)
Estrogen current 655 131 1.06 (0.86, 1.31) 162 31 0.81 (0.53, 1.23) 85 19 1.14 (0.65, 1.99) 51 12 1.12 (0.54, 2.35) 93 16 0.79 (0.43, 1.46)
Estrogen and progesterone current 345 184 2.92 (2.36, 3.62) 89 33 1.74 (1.10, 2.74) 48 18 1.67 (0.89, 3.14) 32 6 0.88 (0.33, 2.30) 49 10 0.92 (0.43, 1.98)
p-trend <0.0001 0.34 0.15 0.77 0.72
p-heterogeneity# 0.05 0.34 0.03 0.01
Duration of hormone therapy (years)
Never 7411 1356 1 Reference 1762 356 1 Reference 1010 195 1 Reference 573 113 1 Reference 991 196 1 Reference
< =3 1625 306 1.09 (0.94, 1.26) 473 96 0.99 (0.76, 1.30) 237 43 0.90 (0.61, 1.34) 134 20 0.66 (0.38, 1.16) 234 41 0.77 (0.52, 1.15)
4–8 1130 240 1.21 (1.03, 1.43) 289 64 1.06 (0.77, 1.46) 155 35 1.19 (0.76, 1.87) 76 19 1.18 (0.65, 2.13) 119 25 0.99 (0.59, 1.67)
>8 1756 555 1.84 (1.61, 2.11) 485 112 1.24 (0.95, 1.61) 253 63 1.34 (0.91, 1.98) 108 23 0.93 (0.52, 1.65) 222 47 1.04 (0.69, 1.56)
p-trend <0.0001 0.15 0.14 0.94 1.00
p-heterogeneity# 0.001 0.48 0.11 0.02
Duration of estrogen and progesterone therapy (years)
Never 7411 1356 1 Reference 1762 356 1 Reference 1010 195 1 Reference 573 113 1 Reference 991 196 1 Reference
< =5 1908 412 1.25 (1.09, 1.43) 545 114 1.02 (0.79, 1.32) 276 45 0.79 (0.53, 1.17) 153 30 0.92 (0.56, 1.53) 230 54 1.19 (0.81, 1.74)
> 5 1796 561 1.80 (1.58, 2.06) 496 116 1.18 (0.90, 1.54) 256 71 1.47 (1.00, 2.16) 105 29 1.04 (0.62, 1.74) 211 52 1.34 (0.89, 2.02)
p-trend <0.0001 0.31 0.27 0.98 0.13
p-heterogeneity# 0.004 0.19 0.19 0.02
aThe category Never was not included in the analysis of p-trend. *p for trend and OR mutually adjusted for age (50–54, 55–59, 60–64, 65–70 years at screening), body mass index (BMI) (≤22, 23–25, 26–28, >28 at
screening), education (no education/primary school, high school, bachelor or master’s degree), age at menarche (9–12, 13, 14, 15–18 years), number of pregnancies (0, 1, 2, 3, ≥4), menopausal status (premenopausal,
perimenopausal, postmenopausal). #p for heterogeneity across subtypes was determined in a case − case model (see “Methods”). ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor
receptor 2
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Table 4 Adjusted odds ratios (OR) and 95% confidence intervals (CI) for association between breast cancer overall and subtypes of
breast cancer, and the duration of estrogen and progestin therapy (EPT) by body mass index (BMI)
OVERALL breast cancer
BMI <25 BMI ≥25
Controls (n) Cases (n) OR* 95% CI Controls (n) Cases (n) OR 95% CI
Duration of EPT (years)
Never used 6154 1056 1 Reference 6880 1402 1 Reference
< =5 1740 316 1.20 (1.00, 1.44) 1812 420 1.13 (0.97, 1.32)
>5 1623 495 1.96 (1.64, 2.34) 1615 456 1.31 (1.12, 1.54)
p-trend* <0.0001 <0.0001
p for interaction 0.001
Luminal A-like breast cancer
Duration of EPT (years)
Never used 3424 550 1 Reference 3892 789 1 Reference
< =5 959 176 1.36 (1.06, 1.74) 987 243 1.22 (0.99, 1.50)
>5 896 293 2.29 (1.80, 2.91) 906 270 1.38 (1.12, 1.71)
p-trend <0.0001 0.002
p for interaction 0.001
Luminal B-like HER2-negative breast cancer
Duration of EPT (years)
Never used 850 173 1 Reference 887 178 1 Reference
< =5 257 57 1.13 (0.74, 1.71) 295 59 0.83 (0.54, 1.29)
>5 243 71 1.22 (0.79, 1.88) 256 47 0.83 (0.51, 1.35)
p-trend 0.34 0.37
p for interaction 0.03
Luminal B-like HER2-positive breast cancer
Duration of EPT (years)
Never used 450 81 1 Reference 544 113 1 Reference
< =5 137 16 0.85 (0.40, 1.81) 144 29 0.82 (0.45, 1.49)
>5 127 28 1.56 (0.67, 3.60) 130 43 1.56 (0.87, 2.78)
p-trend 0.44 0.24
p for interaction 0.52
HER2-positive breast cancer
Duration of EPT (years)
Never used 269 54 1 Reference 296 56 1 Reference
< =5 80 16 1.14 (0.44, 2.95) 77 14 1.38 (0.62, 3.08)
>5 49 13 1.53 (0.57, 4.05) 57 17 1.28 (0.56, 2.93)
p-trend 0.41 0.43
p for interaction 0.89
Triple-negative breast cancer
Duration of EPT (years)
Never used 457 94 1 Reference 522 101 1 Reference
< =5 123 20 0.96 (0.45, 2.04) 110 34 1.40 (0.79, 2.47)
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largest single studies of breast cancer subtypes. The
number of previous pregnancies was associated with a
decreased risk, and late age at first birth was associ-
ated with an increased risk of luminal-like subtypes.
Although not statistically significant, number of preg-
nancies and age at first birth were also associated
with HER2-positive and triple-negative breast cancer.
There were larger differences between subtypes with
the use of exogenous hormones. Duration of oral
contraceptive use and IUDs were weakly associated
with luminal A-like breast cancer, while current EPT
was associated with an almost threefold increased risk
of luminal A-like breast cancer, but was not associ-
ated with either HER2-positive or triple-negative
cancer.
There have been different methods of classifying
breast cancer subtypes. In our study we used the
classification from the St. Gallen meeting in 2013
[46] where we included only ER+ PR+ HER2- as
luminal A, while ER+ PR- HER2- was classified as
one of the luminal B definitions, while the second
luminal B subtype was the one that is more com-
monly referred to as luminal B, i.e. ER+ and/or PR+
HER2+. In contrast, in the systematic review of 38
studies [47] they used a wider definition of luminal A
(ER+ and/or PR+ and HER2-), and only one luminal
B subtype (ER+ and/or PR+ HER2+). Some studies
have also added on Ki67 to the definition of luminal
B [40, 48, 49], which may give a more precise defin-
ition of luminal B, although Ki67 is notoriously diffi-
cult to assess [55]. Although our luminal A results
were much in line with previous studies, there were
some slight differences between our study and previ-
ous studies of luminal B, as discussed below.
In the current study we also examined triple-negative
breast cancer (ER- PR- HER2-). Some studies have
added additional markers, to better define the subset
that is basal-like, by HER1+ and/or cytokeratin 5/6+ [9,
39, 40, 49, 56]. As discussed subsequently, this may ex-
plain some discrepancies between the results of different
studies.
Reproductive factors
Our observation of an inverse association between
parity and luminal A-like breast cancer is consistent
with the vast majority of studies as summarized in
the recent systematic review of 38 studies [47] and
the more recent studies that were not included in
the review [7, 8, 10, 48–51]. The results for luminal
B breast cancer have been less clear, with studies
finding a protective or increased effect, or no effect
of parity [47–50]. In the current study, parity was
associated with a decreased risk of both luminal B-
like subtypes. This is consistent with four out of six
studies included in the systematic review [47] and
three of the more recent studies [48–50]. Two of these
recent studies had information on Ki-67 [48, 49]. When
we added grade to the luminal A-like and luminal B-like
subtypes, the parity results remained largely the same.
These results suggest that there is a protective effect
against luminal B, and the effect seems apparent
regardless of the markers used to define the luminal B
subtype.
Although not statistically significant, we found that
parity was associated with a decreased risk of HER2-
positive breast cancer. This is consistent with the find-
ings in the Nurses’ Health Study [49], but inconsistent
with a case–control study from the Breast Cancer Family
Registry [50] and a Korean cohort study [48], which re-
ported that parity was associated with an increased risk
of the HER2-positive subtype. One of these latter studies
included very few women with HER2-positive breast
cancer and both studies included younger women than
the current study.
However, although not statistically significant, we
found that parity was associated with a decreased risk of
triple-negative breast cancer.
This is inconsistent with several other studies in
which parity was associated with no risk [48], or was
associated with increased risk of triple-negative breast
cancer [7, 47, 50]. One of the studies was in African
American women who are less likely to breastfeed com-
pared to Caucasian women [7]. Several studies have used
CK5/6 and epithelial growth factor receptor (EGFR) in
addition to ER, PR and HER2neu to define a basal-like
subtype [9, 39, 40, 49, 56], and this may be one reason for
the inconsistency between our study and these other stud-
ies. We included 386 women with triple-negative breast
cancer in our study, but few of these had never been preg-
nant (n = 34) or had four or more children (n = 36). More
Table 4 Adjusted odds ratios (OR) and 95% confidence intervals (CI) for association between breast cancer overall and subtypes of
breast cancer, and the duration of estrogen and progestin therapy (EPT) by body mass index (BMI) (Continued)
>5 113 25 1.27 (0.56, 2.86) 100 27 1.34 (0.71, 2.54)
p-trend 0.63 0.25
p for interaction 0.09
*p for trend and ORs mutually adjusted for age (50–54, 55–59, 60–64, 65–70 years at screening), BMI (≤22, 23–25, 26–28, >28 at screening), age at menarche
(9–12, 13, 14, 15–18), education (no education/primary school, high school, bachelor’s or master’s degree), number of pregnancies (0, 1, 2, 3, ≥4),
menopausal status (premenopausal, perimenopausal, postmenopausal). HER2 human epidermal growth factor receptor 2
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notably, our study consisted of older women (aged 50–69
years). Although we did not have information on time
since the last pregnancy, we can only speculate that few
women in our study had had a recent pregnancy, a factor
associated with increased risk of triple-negative cancer
[57]. Perhaps this explains why we did not find an
increased risk of triple-negative cancer with multi-parity.
We found that age at first birth (26 years or older)
was associated with an increased risk of luminal-like
breast cancer. This is consistent with a systematic
review and [47] and two recent studies [8, 49]. How-
ever, age at first birth was only statistically signifi-
cantly associated with luminal A cancer, whereas in
the current study age at first birth was significantly
associated with luminal A-like and luminal B-like
HER2-negative subtypes. One reason for this differ-
ence might be that our definition of luminal B-like
HER2-negative cancer was rather similar to the
definition of the luminal A-like subtype used in the
other studies. In the current study, a non-statistically
significant positive association was observed between
late age at first birth (31 years or older), and both
HER2-positive and triple-negative breast cancer. This
is consistent with the Nurses’ Health Study [49], and
inconsistent with the case-control study from Korea
[8]. In the latter study, the majority of women were
premenopausal, whereas the current study included
mainly postmenopausal women.
We found no protective effect of breastfeeding on
breast cancer occurrence overall or for any subtype.
This is inconsistent with the systematic review that
reported that breastfeeding is associated with de-
creased risk of luminal A-like, luminal B-like and
triple-negative subtypes [47].This may be because our
study only included women above 50 years of age,
and is consistent with the suggestion that the pro-
tective effect of breastfeeding is relatively time-
limited, and may be seen predominantly in younger
women [58–60]. Several of the more recent studies
found a significant protective effect against basal-like
breast cancer [7, 49–51]. These studies included both
triple-negative breast cancer as in our study and
basal-like breast cancer with more markers (CK 5/6
and EGFR) [49].
Oral contraceptives, intrauterine devices, and menopausal
hormone therapy use
For long duration of oral contraceptive use (>10 years),
we observed a slight increase in risk of all the subtypes
except for the luminal B-like HER2-positive and HER2-
positive subtypes. Our positive association between dur-
ation of oral contraceptive use and triple-negative breast
cancer is consistent with the systematic review [47].
However, two of the three studies in the review reported
a decreased risk between oral contraceptive use and the
luminal A subtype [9, 34]. These latter studies were
smaller and included younger women (20–74 and
<56 years old) than the current study. There are few data
on IUD use. Two studies reported that IUDs were not
associated with an increased risk of breast cancer [61,
62], whereas other studies report that IUDs were associ-
ated with an increased breast cancer risk [63, 64]. We
observed a significant positive trend for association be-
tween duration of IUD use and breast cancer overall and
luminal A-like breast cancer. However, the increased risk
of luminal A-like breast cancer was only statistically sig-
nificant in women using IUDs for more than 10 years.
This is consistent with two Finnish studies of
levonorgestrel-releasing IUDs and breast cancer [63, 64],
which reported that levonorgestrel-releasing IUDs were
associated with an increased risk of breast cancer. One
hypothesis is that levonorgestrel-releasing IUDs have
substantial progestogenic and androgenic effects [63,
64], which could contribute to this increased risk with
IUD use.
We observed a large increased risk of luminal A-like
and a moderate increased risk of luminal B-like breast
cancer with use of menopausal hormone therapy, albeit
only significantly so for the luminal A-like subtype. This
is consistent with a systematic review [47] and the
cohort study from the Nurses’ Health Study that investi-
gated only one luminal B subtype, and used Ki-67 to dif-
ferentiate between luminal A-like and luminal B-like
subtypes [49]. There was some evidence that meno-
pausal hormone therapy was associated with a slightly
decreased risk of triple-negative breast cancer when we
compared current menopausal hormone therapy users
to never users. This is consistent with one of the studies
in the systematic review, which was a case-control study
from Washington state [35]. The latter study used the
same definition of triple-negative breast cancer as the
current study. Inconsistent with our result, studies from
the Women’s Health Initiative [65] and the Nurses’
Health Study [40, 49] reported an association between
menopausal hormone therapy and increased risk of
triple-negative breast cancer. In these latter studies, they
used more biomarkers (CK 5/6 and EGFR) to define the
basal-like subtype and included younger women than
the current study. When we looked at the duration of
EPT, compared to never users, women who had used
EPT for more than 5 years were at an increased risk of
HER2-positive and triple-negative breast cancer. This is
consistent with the analysis from the Nurses’ Health
Study [49].
We hypothesized that EPT would have a stronger
effect on thin women than on heavier women, and our
results suggested modification of the effect of the dur-
ation of EPT when we analyzed leaner women (BMI
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<25) and heavier women (BMI >25) with the luminal-
like subtypes of breast cancer. This is consistent with a
previous population-based case–control study of women
aged 55–72 years [66].
Mechanisms and suggested subtype differences
Pregnancies have been reported to ultimately reduce
plasma estrogen (estrone, estradiol and estriol) [67] and
follicular-phase progesterone [68], and increase sex
hormone-binding globulin [67]. Our findings suggest
that both parity and combined menopausal hormone
therapy may be predominantly associated with luminal-
like breast tumors, with the association being strongest
for the luminal A-like subtype. The effect of EPT was
stronger when we added grade to the definition of
luminal A cancer. We observed little effect of breast-
feeding overall, and no clear subtype differences. It is
possible that the effect of breastfeeding is non-
hormonal, and includes changes in immune responses
and apoptosis [69, 70].
Our results, together with those from other large stud-
ies, further suggest that the associations between these
hormonal-related factors (parity, age at first birth, oral
contraceptive use and menopausal hormone therapy
use) and risk of the luminal B-like subtypes are similar
to the associations between these factors and risk of the
luminal A-like subtype. However, although the associ-
ation with luminal A was the strongest, it is clear that
EPT also increases the risk of breast cancer with bad
prognosis [71].
We observed some intriguing associations with HER2-
positive breast cancer. The effect of pregnancies and age
at first birth were similar for the HER2-positive subtype
and luminal cancer. Also, age at menopause was strongly
associated with increased risk only of the HER2-positive
subtype. Further, we observed a positive trend of associ-
ation between age at menopause and the luminal B-like
HER2-positive subtype. These results might imply that
there are hormonal mechanisms involved in the expres-
sion of the HER2 protein. On the other hand, exogenous
hormone use (EPT) was not associated with this sub-
type, suggesting that perhaps only some hormonal
mechanisms play a role in HER2-positive subtypes. The
contrasting results between the luminal-like subtypes
and triple-negative breast cancer are also consistent with
previous literature. Hormonal factors have a stronger ef-
fect on ER+ PR+ tumors, which suggests that the
etiology of triple-negative cancer is different from that of
the luminal subtypes. Specifically, this suggests that
triple-negative tumors may not be as easily prevented
hormonally.
In summary, the strongest discrepancy across subtypes
was for the use of combined hormone therapy, where
the effect was clearly much stronger for luminal A-like
than for other cancers. Otherwise, the associations with
hormonal risk factors were stronger for luminal A and
B-like subtypes than for HER2-positive and triple-
negative subtypes. Our results suggest that reproductive
factors may to some extent be associated with HER2-
positive tumors, but that triple-negative tumors have a
different etiology.
Strengths and limitations
Strengths of this study include its population-based
design, the large size, being the largest single study of
breast cancer subtypes conducted so far, and the avail-
ability of prospectively collected detailed information on
many risk factors for breast cancer.
Although the study is the largest to date, there was
still limited power for analysis of the rare breast can-
cer subtypes. Another weakness was the lack of mo-
lecular expression data. This may have obscured
differences between the subtypes. Another possible
weakness was that a subset of women were diagnosed
within a month of completing the questionnaire (n =
1813), and could have been symptomatic when they
completed their questionnaire. However, exclusion of
women who were diagnosed within a month of com-
pleting the questionnaire did not affect the results
(results not shown).
Women who attend screening might be more
health-conscious and have a healthier lifestyle than
women who do not attend. This could have contrib-
uted to obliteration of protective effects of “healthy”
habits, such as an effect of breastfeeding overall. At
the same time, women who attend screening are
more likely to have breast cancer detected. Thus, the
picture becomes complicated with these potential
biases, and it is not clear how this would explain the
results of this paper. The associations between well-
established risk factors and overall risk of breast
cancer were largely as expected. Furthermore, it is
unlikely that any such bias would have differentially
affected the results for different subtypes.
Conclusions
Reproductive factors and menopausal hormone ther-
apy use were more strongly associated with luminal-
like breast cancer, but reproductive factors were also
associated with HER2-positive and triple-negative
breast cancer. The differences between subtypes were
greatest for menopausal hormone use. Our results
add to the literature showing that there are etiologic
differences between luminal breast cancer subtypes
and basal-like or triple-negative breast cancer
subtypes, but suggest that the differences may be
limited.
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